Retrospect on Endothelin-1 gene (EDN1) polymorphisms in essential hypertension

  • Win Min Oo Department of Biochemistry, University of Medicine-Magway, Myanmar
  • Myat Mon Khine Department of Biochemistry, University of Medicine-Magway, Myanmar

Abstract

Hypertension is a major health challenge to both public and clinical fields worldwide. The etiology of essential hypertension is complex, involving the interactions between several genes and environmental factors. In recent years, researchers have evaluated different single gene polymorphisms to determine whether genetic variations affect hypertensive risk or not. Among the several genetic variations, endothelin-1 gene polymorphism become a popular interest to determine hypertensive risk in different study groups. Despite normal endothelin-1 level in essential hypertension, EDN1 gene is overexpressed in hypertensive patients. In this review, an evaluation of scientific data that how EDN1 gene polymorphisms are implicated in hypertension has been carried out. Certain gene variants of endothelin-1 gene carry hypertensive risk in some studies, yet various effects and other interacting factors have been identified.  Adenine insertion/deletion polymorphism at 5’ untranslated region of EDN1 gene affects variations of blood pressure as the insertion variant overexpresses EDN1 by mRNA stability and is associated with high diastolic pressure. Yet, metabolic dysfunctions are absent in hypertensive patients carrying the insertion genotype. The Guanine-to-Thymine transversion at position 198 of EDN1 gene is another variation affecting hypertensive risk. The T allele is the predictor for high blood pressures – both systolic and diastolic. However, some factors such as obesity, fitness level and physical training interacts with the association. The evidence of other single nucleotide polymorphisms of EDN1 associating with hypertension is poor.

References

Ahn D, Ge Y, Stricklett PK et al (2004) Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 51:1605-1610

Arima H, Barzi F, Chalmers J (2011). Mortality patterns in hypertension. J Hypertens Suppl 1:3-7

Asai T, Ohkubo T, Katsuya T et al (2001). Endothelin1 gene variant associates with blood pressure in obese Japanese subjects: the Ohasama Study. Hypertension 38:1321-1324

Barton M (2008) Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 4(9):490-501

Barton M, Shaw D, d'Uscio LV, Moreau P et al (1997) Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238(3):861-865

Berge K, Berg K (1992) No effect of a Taq1 polymorphism in DNA at the endothelin (EDN1) locus on normal blood pressure level or variability. Clinical genetics 41(2):90-95

Bloch K, Friedrich S, Lee M et al (1989) Structural organization and chromosomal assignment of the gene encoding endothelin. J Biol Chem 264:10851-10857

Brown M, Sharma P, Stevens P (2000) Association between diastolic blood pressure and variants of the endothelin-1 and endothelin-2 genes. J Cardiovasc Pharmacol 35(Suppl2):41-43

Butler M (2010) Genetics of hypertension. Current status. J Med Liban 58(3):175-178

Dhaun N, Goddard J, Kohan D (2008) Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 52:452-459

Dong Y, Wang X, Zhu H, Treiber F, Snieder H (2004) Endothelin-1 gene and progression of blood pressure and left ventricular mass. Hypertension 44:884-890

Dzholdasbekova A, Gaipov A (2010) The association between polymorphism of Lys198Asn of endothelin-1 gene and arterial hypertension risk in Kazakh people. Euro J Gen Med 7(2):187-191

Fan X, Wang H, Gao L et al (2012) The association of an adenine insertion variant in the 5' UTR of endothelin 1 gene with hypertension and orthostatic hypotension. Arch Med Sci 2:219-226

Fang Z, Li M, Ma Z et al (2017) Association of endothelin-1 gene polymorphisms with essential hypertension in a Chinese population. Genetics and Molecular Research 16(3):1-7

Feri C, Bellini C, Desideri G et al (1999). Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 44:431-436

Haynes W, Strachan FW (1995 Endothelin ETA and ETB re4ceptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 92:357-363

Hickey K, Rubanyi G, RJ Paul, Highsmith RF (1985) Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. American journal of physiology 248(5 Pt 1), C550-556

Hoehe M, Ehrenreich H, Caenazzo L, Berrettini W (1991) Taq1 identifies a four allele DNA polymorphism of the human endothelin-1 gene (EDN1) Nucleic acid research 19(11):3161

Iglarz M, Benessiano J, Philip I et al (2012) Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension 39:2009-2013

Inoue A, Yanagisawa M, Kimura S et al (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proceedings of the national academy of science of the United States of America 86(8):2863-2867

Jin J, Nakura H, Wu Z et al (2003) Association of endothelin-1 gene variant with hypertension. Hypertension 41:163-167

Kaetsu A, Kishimoto T, Osaki Y et al (2004) The lack of relationship between an endothelin-1 gene polymorphism (Ala288Ser) and incidence of hypertension: a retrospective cohort study among Japanese workers. Journal of Epidemiology 14(4):129-136

Kearney P, Whelton M, Reynolds K et al (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365(9455):217

Kohan D (2009) Biology of endothelin receptors in the collecting duct. Kidney Int 76:481-486

Kohan D (2010) Endothelin, Hypertension and chronic kidney disease: New insights. Curr Opin Nephrol Hypertens 19(2):134-139

Krum H, Viskoper R, Lacourciere Y, Budde M, Charlon V (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigator. N Engl J Med 338(12):784-790

Lackland D (2005) Systemic hypertension: an endemic, epidemic, and a pandemic. Semin Nephrol 25(4):194-197

Lassen O, Herrera J, Dotto G et al (2016) Plasmatic biochemical variables associated with polymorphisms in the endothelin-1 and endothelin-1 receptor a gene in hypertensive patients: pilot study. British Journal of Medicine & Medical Research 11(7):1-8

Lu J, Lu Y, Wang X et al (2017) Prevalence, awareness, treatment and control of hypertension in China: data from 1.7 million adults in a population-based screening study (Chinese PEACE Million Persons Projects). Lancet, 390(10112):2549

Marius B, Htet A, Haakon E et al (2016) Prevalence and determinants of hypertension in Myanmar - a nationwide cross-sectional study. BMC Public Health 16:590

Munter P, Carey RG, Jones D et al (2018) Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation 137(2):109

Ohuchi T, Kuwaki T, Ling G et al (1999) Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol 276(4) R1071-1077

Popowski K, Sperker B, Kroemer H, John U, Laule M, Stangl K (2003) Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene. Pharmacogenetics 13:445-451

Prasad VS, Palaniswamy C, Frishman WH (2009) Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev 17:181–191

Rankinen T, Church T, Rice T et al (2007) Effect of endothelin-1 genotype on blood pressure is dependent on physical activity or fitness levels. Hypertension 50:1120-1125

Schiffrin E (2001) Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14:83-89

Schiffrin E, Dang L, Sventek P, Day R (1997) Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 15:57-63

Stephen B, Steven R, Warren S, Deborah G, Thomas B (2007) Designing Clinical Research (3 ed.). Lippincott Williams & Wilkins

Stevens P, Brown M (1995) Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol 25:9-12

Strachan F, Spratt J, Wilkinson I, Johnston N, Gray G, Webb D (1999) Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33(1):581-585

Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A (1999) Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 100(16):1680-1683

Tanaka C, Kamide K, Takiuchi S, Kawano Y, Miyata T (2004) Evaluation of the Lys198Asn and +134delA genetic polymorphisms of the endothelin-1 gene. Hypertension research 27(5):367-371

Tiret L, Poirier O, Hallet V, McDonagh T et al (1999) The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 33:1169-1174

Treiber F, Barbeau P, Harshfield G, Kang H, Pollock D, Pollock J, Snieder H (2003) Endothelin-1 gene Lys198Asn polymorphism and blood pressure reactivity. Hypertension 42:494-499

Turner A, Murphy L (1996) Molecular pharmacology of endothelin converting enzymes. Biochemical pharmacology 51(2):91-102

Wolpert H, Steen S, Istfan N, Simonson D (1996) Insulin modulates circulating endothelin-1 levels in humans. Metabolism 9:1186-1191

Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163):411-415
Published
2018-06-30
How to Cite
[1]
Oo, W. and Khine, M. 2018. Retrospect on Endothelin-1 gene (EDN1) polymorphisms in essential hypertension. Journal of Biological Sciences and Medicine. 4, 2 (Jun. 2018).
Section
Mini-Reviews